http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-3772270-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_2ca2e4410855da087e11bf3eea8933fa |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07H17-08 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07H17-08 |
| filingDate | 1969-11-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 1973-11-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_27ce514b6034d3ca009d1b544b44c41d http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6e7dcbf4d68ae392812967f5fcebf24f |
| publicationDate | 1973-11-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | US-3772270-A |
| titleOfInvention | Erythromycylamine and erythromycyl b amine |
| abstract | ERYTHROMYCYLUMINE AND ERYTHROMYCYL B AMINE ARE PREPARED BY THE HYDROGENATION OF THE OXIME, THE HYDRAZINE ADDUCT OR THE N-ISOPROPYLIDENE DERIVATIVE OF THE HYDRAZINE ADDUCT OF ERYTHROMYCIN OR OF ERYTHROMYCIN B USING A NOBLE METAL CATALYST. ERYTHROMYCYLAMINE AND ERYTHROMYCYL B AMINE ARE ARTIBIOTICALLY ACTIVE BOTH IN VITRO AND IN VIVO AND NOT ONLY ENJOY AN INCREASED STABILITY TOWARDS ACID, BUT ALSO DEMONSTRATE A LOWER INCIDENCE OF SIDE EFFECTS WHEN ADMINISTERED IN VIVO AS COMPARED WITH ERYTHROMYCIN ITSELF. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-RE39531-E http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2004022740-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-5110800-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-4945080-A |
| priorityDate | 1969-11-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 46.